• Skip to primary navigation
  • Skip to main content
  • Skip to footer
NICO CorporationSecondary logo

NICO Corporation

Dedicated to revolutionizing minimally invasive neurosurgery

  • Home
  • Patients
  • Professionals
    • Our Capabilities
    • Our Integrated System
    • Our Surgical Focus
    • Our Impact
    • Published Data
    • Global Distribution
    • NICO Technologies for Pre-Clinical Research
    • Medical Education
    • ENRICH Clinical Trial
  • Company
    • Our Mission
    • Our Leadership Team
    • News & Events
  • LinkedIn
  • Twitter
  • YouTube

NICO Awards $40,000 Grant to London’s Kings College Hospital

Home » NICO Awards $40,000 Grant to London’s Kings College Hospital

October 12, 2023 by admin

For Immediate Release

Contact: Sue Goin
sue.goin@sapphire-com
317.402.8690

Download Press Release (PDF)

Study outcomes could provide insights into new targeted treatments to manage this challenging disease

INDIANAPOLIS, IN (October 12, 2023) – Ranjeev Bhangoo, MD, and Jose Lavador, MD, neurosurgeons from Kings College Hospital in London, have received a $40,000 Investigator Initiated Study (IIS) grant from NICO Corporation to assess differences in the microstructural improvement of brain fiber tracts between Minimally Invasive Parafascicular Surgery (MIPS) with NICO’s BrainPath and a conventional surgical approach after deep-seated tumor removal. The study aims to correlate these differences with associated clinical repercussions and patient functional outcomes that ultimately impact treatment decisions.

Study investigators believe this kind of analysis can provide crucial information to current research in neuro-oncology. Dr. Bhangoo is Clinical Director of Neuroscience and Dr. Lavador a Consultant Neurosurgeon at King’s College Hospital. They are seeking a better understanding of the impact NICO technologies have on patient recovery. Existing published data suggests that NICO technologies cause less damage to brain fiber tracts when accessing tumors in deep subcortical regions of the brain.

The MIPS CONNECT study will use high-quality tractography to assess the impact of MIPS in the subcortical connectome, both in terms of anatomical and microstructural preservation after tumor resection, as well as potential microstructural improvement at follow-up. The study includes 20 patients undergoing brain surgery using MIPS and 10 using a conventional approach that includes surgical navigation across or through critical brain fiber tracts.

“We believe this study may provide evidence on white matter preservation differences between navigated transgyral and transsulcal (MIPS) approaches and the impact for potential regeneration of these tracts during follow-up,” said Drs. Bhangoo and Lavador. “We believe MIPS using NICO technologies will improve patient outcomes over other surgical approaches, and we expect our study data to indicate a direct correlation of less disruption to white matter to these improvements.”

The MIPS CONNECT study may also provide information associating the potential of fiber tract recovery with distance to the surgical cavity. Bhangoo and Lavador say it may also lead to the development of imaging biomarkers, with potential for integration in risk stratification scores and surrogate markers for functional outcomes.

“We already know through our experience with MIPS and BrainPath that the way you access the subcortical surgical space matters in the treatment of deep-seated lesions. Accessing these lesions in highly eloquent areas of the brain may leave patients susceptible to transitory neurological deficits,” said Jim Pearson, president and CEO of NICO. “Further understanding the potential for recovery due to tract preservation is crucial for treatment decisions, and we are proud to support research of this kind that ultimately helps patients.”

The NICO Investigator Initiated Study (IIS) grant program is dedicated to supporting novel pre-clinical and clinical research efforts related to improved patient and economic outcomes using NICO technologies. The program supports physicians and researchers across a wide range of neuro-specialties committed to building clinical and scientific data to achieve better outcomes for patients and healthcare providers, as well as expanding the body of evidence for vascular, tumor and oncology clinical practices. Learn more about the IIS program areas of interest and how to apply for a grant.

NICO is a pioneer and leader in minimally invasive neurosurgery. It advocates for and supports development of scientific evidence promoting safe and novel approaches to brain disorders and expanding clinical research efforts in pursuit of improved patient outcomes using Minimally Invasive Parafascicular Surgery (MIPS). All projects supported by the IIS grant program are conducted by the applicant(s) and their respective affiliate institution(s); NICO is neither involved in collecting information, conducting research, nor in the publication of any study project findings.

Learn about NICO technologies at NICOneuro.com; follow us on LinkedIn and Twitter, view surgical and patient videos on YouTube.

 

# # #

 

Press Release

Footer

OUR MISSION is SIMPLE

We provide proven and patented technologies that integrate imaging and intervention for a safe, minimally disruptive approach to brain surgery. This integration drives efficiencies for the patient, surgeon and healthcare provider.

Customer Service

 Tel: (317) 660-7118
 Email Us

Follow NICO Here

  • LinkedIn
  • Twitter
  • YouTube
Social Media Links

Search Our Website

privacy policy   ·    ethics hotline   ·    terms of use   ·    patents    ·   labeling

Copyright © 2025 · Nico Corporation · NICO Myriad and BrainPath are “tools” not “treatments”. Physicians should use their best judgment and clinical experience when deciding how to use the Myriad and BrainPath. The latest information, including contraindications, warnings and precautions can be obtained by consulting product labeling or your local NICO representative.